Although an aberrant fusion of TMPRSS2 with ERG or with other oncogenes, including ETV1, ETV4, and ETV5, is a common trait in prostate cancer,224 decreasing the TMPRSS2 expression by inhibition of androgen signaling via use of antiandrogens or ADT that are standard therapies for prostate cancer may be a novel approach against SARS-CoV-2 infection.225 Although the safety and effectiveness of these treatments have been well demonstrated in prostate cancer researches,225 more preclinical researches are still required to evaluate these novel approaches against SARS-CoV-2 infection. The gene discussed is ETV4; the disease is prostate carcinoma.